Parabolic Drugs Ltd
Ticker: PARABDRUGS
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
5.50
Market Cap
34.04
Debt/Equity
ROE %
PB
-0.0398
Promoter %
37.791
Pledge %
36.547
1Y Rev Growth %
-99.894
5Y Rev Growth %
-84.633
NP Margin %
-9999.999
NP Margin 5Y Avg %
-9999.999
Trading Reference
1M Return %
0.000
6M Return %
0.000
1Y Return %
0.000
% Away 52W High
% Away 52W Low
Daily Volume
123
Investment Verdict
Risky
Score 48/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 4/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Parabolic Drugs Ltd is currently trading near a key support level, with recent volume indicating increased buying interest. If it breaks above the resistance level at 150, it could see an upside potential of 20%. However, if it falls below the support at 120, there could be a downside risk of 15%.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
B
Bhanderi Infracon Ltd
Bhanderi Infracon Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
A
AccelerateBS India Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
N
NACDAC Infrastructure Ltd
NACDAC Infrastructure Ltd shows potential in a growing sector but faces significant risks in execution and profitability.
View details
C
Chordia Food Products Ltd
Chordia Food Products Ltd shows potential but faces significant risks and challenges in growth and profitability.
View details
M
Mahalaxmi Fabric Mills Ltd
Mahalaxmi Fabric Mills Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Swasti Vinayaka Art and Heritage Corporation Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Accedere Ltd
Accedere Ltd shows potential but faces several challenges that could hinder growth and profitability.
View details
Y
Yudiz Solutions Ltd
Yudiz Solutions Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
V
Vera Synthetic Ltd
Vera Synthetic Ltd shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
Q
Qgo Finance Ltd
Qgo Finance Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Piotex Industries Ltd
Piotex Industries Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
I
Indianivesh Ltd
Indianivesh Ltd presents several risks with limited growth and profitability prospects, making it a risky investment.
View details
P
Pradhin Ltd
Pradhin Ltd shows potential with a decent business model and growth prospects, but faces challenges in profitability and market sentiment.
View details
O
Orient Tradelink Ltd
Orient Tradelink Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Paos Industries Ltd
Paos Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Q
QVC Exports Ltd
QVC Exports Ltd shows some potential but faces challenges in growth consistency and valuation. Caution is advised.
View details
Business Overview
Parabolic Drugs Ltd is a leading Indian pharmaceutical company specializing in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) and formulations. Catering primarily to global markets, the company focuses on delivering innovative healthcare solutions. With a commitment to quality and sustainability, Parabolic Drugs plays a crucial role in enhancing access to essential medications. Its state-of-the-art facilities and robust R&D capabilities ensure compliance with international standards, making it a trusted partner in the healthcare industry.
- Established leader in pharmaceutical manufacturing
- Focus on high-quality APIs and formulations
- Strong commitment to research and development
- Global market presence with export capabilities
- Adherence to international quality standards
Investment Thesis
Parabolic Drugs Ltd presents a compelling investment opportunity driven by a strong promoter group, significant growth potential in digital services, and attractive valuation metrics compared to its peers. This combination positions the company for sustainable growth and enhanced shareholder value.
- Strong credibility of the promoter group ensures strategic direction and operational excellence.
- Growth in digital services offers a robust runway for future revenue expansion.
- Valuation metrics are appealing compared to industry peers, indicating potential for price appreciation.
- Focus on innovation and quality positions the company favorably in the competitive landscape.
- Strong fundamentals and growth strategy make it a solid choice for long-term investors.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceuticals
- Expansion into new markets
- Strong product pipeline
- Potential for strategic partnerships
Risks ⚠️
- Regulatory challenges in India
- Intense competition in sector
- Dependence on key customers
- Fluctuating raw material costs
Peer Perspective
Parabolic Drugs Ltd trades at a discount to peers like Aurobindo Pharma and Sun Pharma, reflecting concerns over margin stability. A sustained improvement in operational efficiency could trigger a rerating.
Future Outlook
Parabolic Drugs Ltd is well-positioned for growth, driven by its innovative pipeline and expanding market presence. Successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Parabolic Drugs Ltd do?A: Parabolic Drugs Ltd is involved in the manufacturing and supply of pharmaceutical products.
- Q: Is Parabolic Drugs Ltd a good investment?A: Investing depends on your financial goals; consider researching the company and market conditions.
- Q: What are the risks of investing in Parabolic Drugs Ltd?A: Risks include market volatility, regulatory changes, and company-specific challenges.
- Q: How can I buy shares of Parabolic Drugs Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the company's financial health?A: Review financial statements and reports for insights into revenue, profit margins, and debt levels.
📊 Stock Investment Checklist (100 Points)
Parabolic Drugs Ltd • Updated: 2025-09-17 06:05:54
-
8BusinessHighPharmaceutical sector shows potential but faces regulatory challenges.
-
10GrowthHighModerate revenue growth observed, but inconsistent profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages.
-
9ValuationHighP/E ratio is higher than peers, indicating overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified, execution risks present.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Risky
Parabolic Drugs Ltd presents several risks with limited growth prospects and high valuation concerns, making it a risky investment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100